Duvortuxizumab
From Wikipedia, the free encyclopedia
ATC code
- none
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Chimeric/humanized hybrid (mouse/human) |
| Target | CD19 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4850H7485N1305O1487S35 |
| Molar mass | 108989.98 g·mol−1 |
Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]
This drug was developed by Janssen Global Services.[3]
